# NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

> **NCT04371224** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan Liposomal Injection [Onivyde]
- **DRUG:** Capecitabine
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT04371224
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-23
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371224, "NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04371224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*